Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 18 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Breast Neoplasms 6 Metastatic Castration-resistant Prostate Cancer 3 Fallopian Tube Neoplasms 3 Triple Negative Breast Neoplasms 2 Neoplasm Metastasis 2 Endometrial Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Carcinoma 2 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Hematologic Neoplasms 1 HER2-ve Metastatic Breast Cancer 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Fluorouracil 131 Leucovorin 127 Oxaliplatin 93 Bevacizumab 86 Irinotecan 74 Capecitabine 63 Cetuximab 47 Folfox protocol 32 Panitumumab 18 regorafenib 16 trifluridine tipiracil drug combination 15 Drug Therapy 14 Chemotherapy, Adjuvant 13 IFL protocol 10 Floxuridine 10 Radiotherapy 9 Tegafur 7 Neoadjuvant Therapy 7 Levoleucovorin 7 Laparoscopy 7 Aspirin 7 pembrolizumab 6 Trifluridine 6 Celecoxib 6 atezolizumab 5 XELOX 5 Mitomycin 5 Colonoscopy 5 tipiracil 4 sintilimab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Colorectal Neoplasms × olaparib × Clear all

NCT04456699 2024-10-29

LYNK-003

Merck Sharp & Dohme LLC

Phase 3 Completed

335 enrolled 19 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡